We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Contempo 1998 |

Antileukotriene Drugs in the Management of Asthma

Sally E. Wenzel, MD
JAMA. 1998;280(24):2068-2069. doi:10.1001/jama.280.24.2068.
Text Size: A A A
Published online


DESPITE ADVANCES in the understanding and treatment of the inflammatory processes that mediate the clinical symptoms of asthma,1 the mortality and morbidity associated with this disease have not appreciably declined.2 It continues to be imperative to develop new approaches to asthma therapy. Antileukotriene drugs are a novel form of asthma pharmacotherapy and the first new treatment strategy for chronic asthma in 20 years. In experimental studies, cysteinyl leukotrienes (LTC4, LTD4, and LTE4, together known formerly as slow-reacting substance of anaphylaxis or SRS-A) were found to be extremely potent bronchoconstrictors and to attract inflammatory cells, increase mucous production, and alter vascular permeability.3 LTB4 was found to be a potent chemoattractant for neutrophils and eosinophils, but not to have a bronchoconstrictive effect.3 The cysteinyl leukotrienes were also shown to be produced by activated inflammatory cells (eosinophils, basophils, and mast cells) known to be present in the airways of patients with asthma,3 and were recovered in increased amounts at baseline, after allergen challenge, and during asthma exacerbations from bronchoalveolar lavage fluid and urine of patients with asthma.35 These observations suggested that leukotrienes could be important in the clinical symptoms and physiologic changes of asthma, but confirmation of that concept required the development of drugs that either blocked the synthesis of leukotrienes from arachidonic acid (5-lipoxygenase [5-LO] inhibitors and 5-lipoxygenase activating protein [FLAP] inhibitors) or antagonized the activity of the cysteinyl leukotrienes at their receptor, cysLT1 (leukotriene receptor antagonists).


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

22 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.